Lydia Gaba
A5011045410- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Lung Cancer Treatments and Mutations
- Endometrial and Cervical Cancer Treatments
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Lipids, and Metabolism
- Melanoma and MAPK Pathways
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- BRCA gene mutations in cancer
- RNA modifications and cancer
- Ferroptosis and cancer prognosis
- Neuroendocrine Tumor Research Advances
- Lymphoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Reproductive Biology and Fertility
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- Intraperitoneal and Appendiceal Malignancies
- Uterine Myomas and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Immunotherapy and Immune Responses
Hospital Clínic de Barcelona
2016-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2015-2025
Universitat de Barcelona
2013-2025
Spanish Ovarian Cancer Research Group
2022-2024
Breast Cancer Research Foundation
2023
Target (United States)
2023
Barcelona Provincial Council
2020
Fundació Clínic per a la Recerca Biomèdica
2017
Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a variety solid tumors, but most patients exhibit partial or complete resistance to treatment for reasons that are unclear. In this study, we evaluated tumor specimens from 65 with melanoma, lung nonsquamous, squamous cell head and neck cancers who were treated approved PD1-targeting antibodies pembrolizumab nivolumab. Tumor RNA before anti-PD1 therapy was analyzed on nCounter system using PanCancer...
BackgroundWe hypothesized that the abundance of PD1 mRNA in tumor samples might explain differences overall response rates (ORR) observed following anti-PD1 monotherapy across cancer types.Patients and methodsRNASeqv2 data from 10078 representing 34 different types was analyzed TCGA. Eighteen immune-related gene signatures 547 genes, including PD1, were explored. Correlations between each gene/signature ORRs reported literature calculated. To translate silico findings to clinical setting, we...
PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), placebo-controlled double-blinded randomized phase III trial, enrolled patients recurrent epithelial OC, one to two previous chemotherapy lines, PFI Eligible were randomly...
PURPOSE Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity endometrial cancer (EC). The primary end point was to assess progression-free survival (PFS) with once-weekly oral selinexor patients advanced or recurrent EC. PATIENTS AND METHODS ENGOT-EN5/GOG-3055/SIENDO a randomized, prospective, multicenter, double-blind, placebo-controlled, phase III study at 107 sites 10 countries. Patients 18 years older...
Most metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK (MEKi) eventually progress on treatment. Along acquired resistance due to genetic changes, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was analyse retrospectively outcomes for retreated BRAF-directed therapy.One hundred sixteen who received BRAFi-based therapy and, a break, were rechallenged MEKi at 14 centres in Europe, US and Australia...
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance common and constitutes main reason failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results largely deceiving. We analysed time to progression, overall survival, mutational status of RAS, BRAF nuclear p-IGF-1R expression by immunohistochemistry, 470 CRC patients. The effect...
The PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial was amended to prospectively evaluate the safety and efficacy of an individualized starting dose (ISD) regimen niraparib for first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.In phase 3 PRIMA trial, cancer a complete/partial response platinum-based chemotherapy (N = 733) were initially treated fixed (FSD) 300 mg once daily. Subsequently, protocol so enrolled received ISD: 200 daily baseline body weight <...
ObjectiveTo assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received niraparib as first-line maintenance therapy.MethodsPRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) enrolled newly diagnosed advanced OC responded to platinum-based chemotherapy. Patients were randomized (2:1) or placebo once daily 28-day cycles until disease progression, intolerable toxicity, death. HRQoL was assessed a prespecified secondary end point using responses the...
Abstract Introduction Immune check-point inhibitors (ICI) were a major breakthrough in cancer care, but optimal patient selection remains elusive most tumors. Methods Overall 173 adult patients with metastatic solid tumors candidates to ICI clinical trials at our Institution prospectively recruited. Blood samples collected cycle 1 (C1D1) and 2 (C2D1) until the occurrence of progressive disease (PD). C1D1 LIPI, RMH, PMHI, NLR, dNLR, PIPO GRIm prognostic scores calculated. The primary endpoint...
Abstract Purpose Sex influences chemotherapy-induced nausea and vomiting (CINV). However, in clinical practice, males females receive the same antiemetic prophylaxis. We compared CINV between sexes patients with different emetic risk schemes evaluated predisposing factors main adverse effects caused by antiemetics. Methods Prospective observational study conducted a tertiary-care hospital from February 2023 to May 2024 starting chemotherapy or new treatment line. was using MASCC tool, acute...
PURPOSE This phase IIb, single-arm, multicenter, global study (ADAGIO; ClinicalTrials.gov identifier: NCT04590248 ) assessed the efficacy and safety of adavosertib in patients with recurrent/persistent uterine serous carcinoma (USC) who had previously received platinum-based chemotherapy. METHODS Eligible were age 18 years older histologically confirmed USC, treated at least one chemotherapy regimen, evidence measurable disease. Adavosertib was administered orally 300 mg once daily on days...
(1) OBJECTIVE: To assess the performance of CA125, HE4, ROMA index and CPH-I to preoperatively identify epithelial ovarian cancer (EOC) or metastatic in ovary (MCO). (2) METHODS: single center retrospective study, including women with a diagnosis adnexal mass. We obtained AUC, sensitivity, specificity predictive values were for EOC MCO. Subgroup analysis harboring masses inconclusive malignancy by ultrasound features Stage I was performed. (3) RESULTS: 1071 patients included, 852 (79.6%)...
Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, first in developed countries [Sung et al. CA Cancer J Clin 71:209-249, 2021]. Although a majority diagnosed at an early stage with low risk of relapse, important proportion patients will relapse. Better knowledge molecular abnormalities crucial to identify high-risk groups stages as well for recurrent or metastatic disease whom adjuvant treatment must be personalized. The objective this guide summarize...
Abstract In recent years, the incorporation of new strategies to therapeutic armamentarium has completely changed outcomes epithelial ovarian cancer (EOC). The identification predictive and prognostic biomarkers also enabled selection those patients more likely respond targeted agents. Nevertheless, EOC is still a highly lethal disease resistance many these agents common. objective this guideline summarize most relevant manage EOC, help clinician throughout challenging diagnostic processes...
To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer.
6050 Background: Niraparib is approved at a fixed starting dose (FSD) of 300 mg QD for maintenance treatment patients (pts) with recurrent ovarian cancer (OC) achieving complete or partial response to platinum-based chemotherapy based in the ENGOT-OV16/NOVA study. A post-hoc analysis NOVA showed baseline bodyweight (BW) and platelet count (PC) were predictive hematologic toxicities reductions. Following this analysis, PRIMA/ENGOT-OV26/GOG-3012 study was amended prospectively evaluate safety...
Background: Despite impressive progression-free survival (PFS) results from PARP inhibitors (PARPi) in ovarian cancer, concerns about their effect on post-progression treatment outcomes have recently arisen, particularly when administered the relapsed setting. Overlapping mechanisms of resistance between PARPi and platinum been described, optimal therapies upon progression to are unknown. We communicate real-world data (RWD) subsequent chemotherapy used as maintenance cancer relapses,...